PCVX logo

Vaxcyte, Inc. (PCVX) EBITDA

Annual EBITDA:

-$448.08M-$55.99M(-14.28%)
December 31, 2024

Summary

  • As of today, PCVX annual EBITDA is -$448.08 million, with the most recent change of -$55.99 million (-14.28%) on December 31, 2024.
  • During the last 3 years, PCVX annual EBITDA has fallen by -$351.47 million (-363.79%).
  • PCVX annual EBITDA is now -1479.25% below its all-time high of -$28.37 million, reached on December 31, 2018.

Performance

PCVX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXincome statement metrics

Quarterly EBITDA:

-$237.18M-$15.95M(-7.21%)
September 30, 2025

Summary

  • As of today, PCVX quarterly EBITDA is -$237.18 million, with the most recent change of -$15.95 million (-7.21%) on September 30, 2025.
  • Over the past year, PCVX quarterly EBITDA has dropped by -$101.76 million (-75.14%).
  • PCVX quarterly EBITDA is now -1903.23% below its all-time high of -$11.84 million, reached on September 30, 2019.

Performance

PCVX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXincome statement metrics

TTM EBITDA:

-$791.72M-$101.76M(-14.75%)
September 30, 2025

Summary

  • As of today, PCVX TTM EBITDA is -$791.72 million, with the most recent change of -$101.76 million (-14.75%) on September 30, 2025.
  • Over the past year, PCVX TTM EBITDA has dropped by -$276.68 million (-53.72%).
  • PCVX TTM EBITDA is now -5700.12% below its all-time high of -$13.65 million, reached on March 31, 2019.

Performance

PCVX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

PCVX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-14.3%-75.1%-53.7%
3Y3 Years-363.8%-321.9%-372.8%
5Y5 Years-814.4%-1029.0%-836.4%

PCVX EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-363.8%at low-321.9%at low-372.8%at low
5Y5-Year-814.4%at low-1140.4%at low-847.4%at low
All-TimeAll-Time-1479.3%at low-1903.2%at low-5700.1%at low

PCVX EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$237.18M(-7.2%)
-$791.72M(-14.7%)
Jun 2025
-
-$221.23M(-25.8%)
-$689.95M(-11.6%)
Mar 2025
-
-$175.92M(-11.8%)
-$618.23M(-11.7%)
Dec 2024
-$448.08M(-14.3%)
-$157.38M(-16.2%)
-$553.69M(-7.5%)
Sep 2024
-
-$135.42M(+9.4%)
-$515.03M(-5.1%)
Jun 2024
-
-$149.50M(-34.2%)
-$490.16M(-15.2%)
Mar 2024
-
-$111.38M(+6.2%)
-$425.40M(-11.1%)
Dec 2023
-$392.10M(-83.2%)
-$118.73M(-7.4%)
-$382.87M(-17.7%)
Sep 2023
-
-$110.55M(-30.4%)
-$325.42M(-20.0%)
Jun 2023
-
-$84.75M(-23.1%)
-$271.10M(-16.8%)
Mar 2023
-
-$68.85M(-12.4%)
-$232.07M(-16.0%)
Dec 2022
-$214.03M
-$61.28M(-9.0%)
-$200.07M(-19.5%)
Sep 2022
-
-$56.22M(-23.0%)
-$167.44M(-21.9%)
Jun 2022
-
-$45.72M(-24.1%)
-$137.32M(-20.0%)
DateAnnualQuarterlyTTM
Mar 2022
-
-$36.85M(-28.7%)
-$114.46M(-14.2%)
Dec 2021
-$96.61M(-10.0%)
-$28.64M(-9.7%)
-$100.22M(-10.5%)
Sep 2021
-
-$26.11M(-14.2%)
-$90.70M(-6.0%)
Jun 2021
-
-$22.86M(-1.1%)
-$85.61M(-2.4%)
Mar 2021
-
-$22.62M(-18.3%)
-$83.57M(+5.2%)
Dec 2020
-$87.81M(-79.2%)
-$19.12M(+9.0%)
-$88.17M(-4.3%)
Sep 2020
-
-$21.01M(-0.9%)
-$84.55M(-12.2%)
Jun 2020
-
-$20.82M(+23.5%)
-$75.38M(-13.4%)
Mar 2020
-
-$27.21M(-75.5%)
-$66.49M(-25.6%)
Dec 2019
-$49.00M(-72.7%)
-$15.51M(-31.0%)
-$52.93M(-41.4%)
Sep 2019
-
-$11.84M(+0.8%)
-$37.42M(-46.3%)
Jun 2019
-
-$11.93M(+12.6%)
-$25.58M(-87.4%)
Mar 2019
-
-$13.65M
-$13.65M
Dec 2018
-$28.37M
-
-

FAQ

  • What is Vaxcyte, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. annual EBITDA year-on-year change?
  • What is Vaxcyte, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. quarterly EBITDA year-on-year change?
  • What is Vaxcyte, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. TTM EBITDA year-on-year change?

What is Vaxcyte, Inc. annual EBITDA?

The current annual EBITDA of PCVX is -$448.08M

What is the all-time high annual EBITDA for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high annual EBITDA is -$28.37M

What is Vaxcyte, Inc. annual EBITDA year-on-year change?

Over the past year, PCVX annual EBITDA has changed by -$55.99M (-14.28%)

What is Vaxcyte, Inc. quarterly EBITDA?

The current quarterly EBITDA of PCVX is -$237.18M

What is the all-time high quarterly EBITDA for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high quarterly EBITDA is -$11.84M

What is Vaxcyte, Inc. quarterly EBITDA year-on-year change?

Over the past year, PCVX quarterly EBITDA has changed by -$101.76M (-75.14%)

What is Vaxcyte, Inc. TTM EBITDA?

The current TTM EBITDA of PCVX is -$791.72M

What is the all-time high TTM EBITDA for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high TTM EBITDA is -$13.65M

What is Vaxcyte, Inc. TTM EBITDA year-on-year change?

Over the past year, PCVX TTM EBITDA has changed by -$276.68M (-53.72%)
On this page